Products for Research Use Only
RegisterLogin

Lasofoxifene (tartrate)

CAT: 0607-C5637-50Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0607-C5637-50Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
third-generation, non-steroidal selective estrogen receptor modulator (SERM)
CAS Number
190791-29-8
Product Name Alternative
(5R,6S)-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol, (2S,3S)-2,3-dihydroxybutanedioate
Sequence
CP 336,156
Field of Research
Endocrinology and Hormones Estrogen progestogen Receptor
Purity
0.98
Form
A crystalline solid
Solubility
≤1mg/ml in DMSO;1mg/ml in dimethyl formamide
Smiles
OC(C=C1)=CC2=C1[C@@H](C3=CC=C(OCCN4CCCC4)C=C3)[C@@H](C5=CC=CC=C5)CC2.OC([C@@H](O)[C@H](O)C(O)=O)=O
Molecular Formula
C28H31NO2·C4H6O6
Molecular Weight
563.6
Shipping Conditions
Blue ice
Storage Conditions
Store at -20°C.

Chemical Information

Lasofoxifene tartrate

Lasofoxifene Tartrate is the tartrate salt form of lasofoxifene, a non-steroidal, naphthalene-derived, third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic and anti-osteoporotic activities. Upon oral administration, lasofoxifene selectively binds to both estrogen receptor alpha (ERalpha; ESR1) and estrogen receptor beta (ERbeta; ESR2) with high affinity and mimics the effects of endogenous estradiol with varying agonist and antagonist effects in ER-expressing tissues. Blockade of ERalpha by lasofoxifene may potentially inhibit estrogen-dependent cancer cell proliferation in ER-expressing cancers. Lasofoxifene may also bind to the certain mutant forms of ERalpha, including the Y537S ESR1 mutant, making it potentially useful in the treatment of tumors that have acquired resistance to other ER-targeting agents.

CAS Number190791-29-8
PubChem CID3081919
IUPAC Name(2S,3S)-2,3-dihydroxybutanedioic acid;(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
Molecular FormulaC32H37NO8
Molecular Weight563.6
Topological Polar Surface Area148
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count9
Rotatable Bond Count9
Heavy Atom Count41
Formal Charge0
Complexity667
SMILES
C1CCN(C1)CCOC2=CC=C(C=C2)[C@H]3[C@H](CCC4=C3C=CC(=C4)O)C5=CC=CC=C5.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O
InChI
InChI=1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1
InChIKey
INEHJXCWEVNEDZ-LUDNRVPPSA-N
Chemical Structure
2D Structure
2D structure of Lasofoxifene tartrate
CAS: 190791-29-8
CID: 3081919
Formula: C32H37NO8
MW: 563.6
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight563.6
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count9
Rotatable Bond Count9
Exact Mass563.25191714
Monoisotopic Mass563.25191714
Topological Polar Surface Area148 Ų
Heavy Atom Count41
Formal Charge0
Complexity667
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count2
Compound Is CanonicalizedYes

Related Products

CatalogName
B1620-10Tolterodine tartrate
C6718-500Pyrantel tartrate
A8515-5.1Rivastigmine Tartrate
A4654-100Ketanserin tartrate
B2059-50Tylosin tartrate
B1623-5.1Ifenprodil Tartrate
B2059-STylosin tartrate
A8515-10Rivastigmine Tartrate
A5391-5.1Varenicline Tartrate
C6718-100Pyrantel tartrate

Alternative Products

CatalogName
9680-25Lasofoxifene tartrate
HY-A0038-01Lasofoxifene (tartrate)
A18097-5Lasofoxifene Tartrate 5mg
A18097-100Lasofoxifene Tartrate 100mg
A18097-25Lasofoxifene Tartrate 25mg
A18097-10Lasofoxifene Tartrate 10mg
A18097-50Lasofoxifene Tartrate 50mg
A18097-10mM-DLasofoxifene Tartrate 10mM * 1mL in DMSO
HY-A0037-01Lasofoxifene

Popular Products